Role of Quantitative HBsAg Testing in Clinical Practice for People With CHB

Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:Determination of inactive carrier statusPrediction of liver fibrosis/cirrhosisPrediction of hepatocellular carcinoma developmentMonitoring response to treatment, including future HBV treatments in the development pipelinePrediction of HBsAg lossJoining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.Presenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm